Publications 2022

Li RG, Stenberg VY, Larsen RH (2022)
A Novel Experimental Generator for Production of High Purity Lead-212 for Use in Radiopharmaceuticals
J Nucl Med (in press)
DOI 10.2967/jnumed.122.264009, PubMed 35798556

Stenberg VY, Tornes AJK, Nilsen HR, Revheim ME, Bruland ØS, Larsen RH, Juzeniene A (2022)
Factors Influencing the Therapeutic Efficacy of the PSMA Targeting Radioligand ²¹²Pb-NG001
Cancers (Basel), 14 (11)
DOI 10.3390/cancers14112784, PubMed 35681766

Publications 2021

Juzeniene A, Stenberg VY, Bruland ØS, Larsen RH (2021)
Preclinical and Clinical Status of PSMA-Targeted Alpha Therapy for Metastatic Castration-Resistant Prostate Cancer
Cancers (Basel), 13 (4)
DOI 10.3390/cancers13040779, PubMed 33668474

Stenberg VY, Larsen RH, Ma LW, Peng Q, Juzenas P, Bruland ØS, Juzeniene A (2021)
Evaluation of the PSMA-Binding Ligand ²¹²Pb-NG001 in Multicellular Tumour Spheroid and Mouse Models of Prostate Cancer
Int J Mol Sci, 22 (9)
DOI 10.3390/ijms22094815, PubMed 34062920

Publications 2020

Napoli E, Stenberg VY, Juzeniene A, Hjellum GE, Bruland ØS, Larsen RH (2020)
Calibration of sodium iodide detectors and reentrant ionization chambers for ²¹²Pb activity in different geometries by HPGe activity determined samples
Appl Radiat Isot, 166, 109362
DOI 10.1016/j.apradiso.2020.109362, PubMed 32979756

Stenberg VY, Juzeniene A, Bruland ØS, Larsen RH (2020)
In situ Generated ²¹²Pb-PSMA Ligand in a ²²⁴Ra-Solution for Dual Targeting of Prostate Cancer Sclerotic Stroma and PSMA-positive Cells
Curr Radiopharm, 13 (2), 130-141
DOI 10.2174/1874471013666200511000532, PubMed 32389119

Stenberg VY, Juzeniene A, Chen Q, Yang X, Bruland ØS, Larsen RH (2020)
Preparation of the alpha-emitting prostate-specific membrane antigen targeted radioligand [²¹² Pb]Pb-NG001 for prostate cancer
J Labelled Comp Radiopharm, 63 (3), 129-143
DOI 10.1002/jlcr.3825, PubMed 31919866